We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · December 27, 2021

Safe Anti–PD-1 Therapy Discontinuation in Advanced Melanoma

Journal for immunotherapy of cancer


Additional Info

Journal for immunotherapy of cancer
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
J Immunother Cancer 2021 Oct 01;9(10)xx, GT Gibney, J Zaemes, S Shand, NJ Shah, D Swoboda, K Gardner, A Radfar, V Petronic-Rosic, MJ Reilly, WB Al-Refaie, S Rapisuwon, MB Atkins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading